<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR330.html">Part 330
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 330.13  Conditions for marketing ingredients recommended for
                            </h3>
                            <p class="depth0"><em>(a)</em> Before the publication in the Federal Register of an applicable  proposed monograph, an OTC drug product that contains: (1) An active  ingredient limited, on or after May 11, 1972, to prescription use for  the indication and route of administration under consideration by an OTC  advisory review panel, and not thereafter exempted from such limitation  pursuant to Sec. 310.200 of this chapter, or</p><p class="depth0"><em>(2)</em> An active ingredient at a dosage level higher than that  available in an OTC drug product on December 4, 1975, shall be regarded  as a new drug within the meaning of section 201(p) of the act for which  an approved new drug application is required.</p><p class="depth0"><em>(b)</em></p><p class="depth0"><em>(1)</em> An OTC drug product that contains: (i) An active ingredient  limited, on or after May 11, 1972, to prescription use for the  indication and route of administration under consideration by an OTC  advisory review panel, and not thereafter exempted from such limitation  pursuant to Sec. 310.200 of this chapter, or</p><p class="depth0"><em>(ii)</em> An active ingredient at a dosage level higher than that  available in an OTC drug product on December 4, 1975, which ingredient  and/or dosage level is classified by the panel in category I (conditions  subject to Sec. 330.10(a)(6)(i)) shall be regarded as a new drug within  the meaning of section 201(p) of the act for which an approved new drug  application is required if marketed for OTC use prior to the date of  publication in the Federal Register of a proposed monograph.</p><p class="depth0"><em>(2)</em> An OTC drug product covered by paragraph (b)(1) of this section  which is marketed after the date of publication in the Federal Register  of a proposed monograph but prior to the effective date of a final  monograph shall be subject to the risk that the Commissioner may not  accept the panel's recommendation and may instead adopt a different  position that may require relabeling, recall, or other regulatory  action. The Commissioner may state such position at any time by notice  in the Federal Register, either separately or as part of another  document; appropriate regulatory action will commence immediately and  will not await publication of a final monograph. Marketing of such a  product with a formulation or labeling not in accord with a proposed  monograph or tentative final monograph also may result in regulatory  action against the product, the marketer, or both.</p><p class="depth0"><em>(c)</em> An OTC drug product that contains: (1) An active ingredient  limited, on or after May 11, 1972, to prescription use for the  indication and route of administration under consideration by an OTC  advisory review panel, and not thereafter exempted from such limitation  pursuant to Sec. 310.200 of this chapter, or</p><p class="depth0"><em>(2)</em> An active ingredient at a dosage level higher than that  available in any OTC drug product on December 4, 1975, which ingredient  and/or dosage level is classified by the panel in category II  (conditions subject to Sec. 330.10(a)(6)(ii)), may be marketed only  after:</p><p class="depth0"><em>(i)</em> The Center for Drug Evaluation and Research or the Commissioner  tentatively determines that the ingredient is generally recognized as  safe and effective, and the Commissioner states by notice in the Federal  Register (separately or as part of another document) that marketing  under specified conditions will be permitted;</p><p class="depth0"><em>(ii)</em> The ingredient is determined by the Commissioner to be  generally recognized as safe and effective and is included in the  appropriate published OTC drug final monograph; or</p><p class="depth0"><em>(iii)</em> A new drug application for the product has been approved.</p><p class="depth0"><em>(d)</em> An OTC drug product that contains: (1) An active ingredient  limited, on or after May 11, 1972, to prescription use for the  indication and route of administration under consideration by an   OTC advisory review panel, and not thereafter exempted from such  limitation pursuant to Sec. 310.200 of this chapter, or</p><p class="depth0"><em>(2)</em> An active ingredient at a dosage level higher than that  available in any OTC drug product on December 4, 1975, which ingredient  and/or dosage level is classified by the panel in category III  (conditions subject to Sec. 330.10(a)(6)(iii)), may be marketed only  after:</p><p class="depth0"><em>(i)</em> The Center for Drug Evaluation and Research or the Commissioner  tentatively determines that the ingredient is generally recognized as  safe and effective, and the Commissioner states by notice in the Federal  Register (separately or as part of another document) that marketing  under specified conditions will be permitted;</p><p class="depth0"><em>(ii)</em> The ingredient is determined by the Commissioner to be  generally recognized as safe and effective and is included in the  appropriate published OTC drug final monograph; or</p><p class="depth0"><em>(iii)</em> A new drug application for the product has been approved.</p><p class="depth0"><em>(e)</em> This section applies only to conditions under consideration as  part of the OTC drug review initiated on May 11, 1972, and evaluated  under the procedures set forth in Sec. 330.10. Section 330.14(h)  applies to the marketing of all conditions under consideration and  evaluated using the criteria and procedures set forth in Sec. 330.14.  [41 FR 32582, Aug. 4, 1976, as amended at 47 FR 17739, Apr. 23, 1982; 50  FR 8996, Mar. 6, 1985; 55 FR 11581, Mar. 29, 1990; 67 FR 3074, Jan. 23,  2002]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
